AI in Precision Medicine Market by Application, Indication, Tools, & End User -Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET SHARE ESTIMATION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OVERVIEW
• 4.2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION
• 4.3 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER & REGION
• 4.4 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
• 4.5 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
• 5.3 MARKET DYNAMICS
  • 5.3.1 DRIVERS
    • 5.3.1.1 Increase in investments in R&D and rise in demand for personalized medication
    • 5.3.1.2 Advancements in genomic research and data availability
    • 5.3.1.3 Growth in cross-industry collaborations and partnerships
    • 5.3.1.4 Role of regulatory landscape in driving AI adoption in healthcare
  • 5.3.2 RESTRAINTS
    • 5.3.2.1 Increase in data breach concerns
    • 5.3.2.2 High cost of implementation of precision medicine solutions
    • 5.3.2.3 Accuracy challenges in AI adoption for healthcare
  • 5.3.3 OPPORTUNITIES
    • 5.3.3.1 Role of predictive analytics in advancing AI for healthcare
    • 5.3.3.2 Leveraging research pipelines and new drug development for AI in healthcare
  • 5.3.4 CHALLENGES
    • 5.3.4.1 Impact of fairness and bias on AI in healthcare
    • 5.3.4.2 Interoperability challenges due to complexity of AI solutions
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.5 INDUSTRY TRENDS
  • 5.5.1 AI'S GROWING ROLE IN PATIENT-SPECIFIC DATA INTEGRATION AND ANALYSIS
  • 5.5.2 ADVANCEMENTS IN AI-POWERED PREDICTIVE ANALYTICS FOR TREATMENT OPTIMIZATION
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Predictive analytics
    • 5.8.1.2 Neural networks
    • 5.8.1.3 Knowledge graphs
    • 5.8.1.4 Cell and gene therapies
    • 5.8.1.5 AI-driven single-cell analysis
  • 5.8.2 COMPLEMENTARY TECHNOLOGY
    • 5.8.2.1 High-performance computing (HPC)
    • 5.8.2.2 Next-generation sequencing
    • 5.8.2.3 Real-world evidence/Real-world data
    • 5.8.2.4 EHR Integration
    • 5.8.2.5 Digital health platforms
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Cloud computing
    • 5.8.3.2 Blockchain technology
    • 5.8.3.3 Internet of Things (IoT) and wearables
    • 5.8.3.4 Robotics and automation
    • 5.8.3.5 3D printing for personalized implants and devices
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY SCENARIO
• 5.10 PRICING ANALYSIS
  • 5.10.1 INDICATIVE PRICING FOR KEY PLAYERS
  • 5.10.2 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 PATENT ANALYSIS
  • 5.12.1 PATENT PUBLICATION TRENDS
  • 5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE
  • 5.12.3 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA
• 5.14 END-USER ANALYSIS
  • 5.14.1 UNMET NEEDS
  • 5.14.2 END-USER EXPECTATIONS
• 5.15 KEY CONFERENCES & EVENTS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 SANOFI LEVERAGED AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE
  • 5.16.2 IBM'S AI-DRIVEN SOLUTION IMPROVED CLINICAL TRIAL ENROLLMENT AT MAYO CLINIC BY ENHANCING PATIENT MATCHING
  • 5.16.3 ENHANCING PATIENT IDENTIFICATION FOR RARE ONCOLOGY BIOMARKERS THROUGH GENOMIC TESTING AND STRATEGIC COLLABORATION
• 5.17 INVESTMENT AND FUNDING SCENARIO
• 5.18 BUSINESS MODELS
• 5.19 IMPACT OF AI/GEN AI IN PRECISION MEDICINE MARKET
  • 5.19.1 KEY USE CASES
  • 5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.19.2.1 Enhancing patient outcomes with AI-driven predictive analytics at Johns Hopkins Hospital
  • 5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.19.3.1 AI in drug discovery market
    • 5.19.3.2 Genomics market
    • 5.19.3.3 Artificial intelligence market
    • 5.19.3.4 Pharmacogenomics market
  • 5.19.4 USER READINESS AND IMPACT ASSESSMENT
    • 5.19.4.1 User readiness
      • 5.19.4.1.1 Healthcare providers
      • 5.19.4.1.2 Pharmaceutical & biotechnology companies

6 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION

• 6.1 INTRODUCTION
• 6.2 DRUG DISCOVERY & DEVELOPMENT
  • 6.2.1 DRUG DISCOVERY
  • 6.2.2 UNDERSTANDING DISEASES
    • 6.2.2.1 Rise in data mining to link targets to diseases
  • 6.2.3 DRUG REPURPOSING
    • 6.2.3.1 Use of graphs for targeted approach to reduce timelines and costs
  • 6.2.4 DE NOVO DRUG DESIGN
    • 6.2.4.1 Availability of large-scale biomedical datasets and urgent demand for novel treatments for complex diseases
  • 6.2.5 DRUG OPTIMIZATION
    • 6.2.5.1 Need to process extensive data on molecular properties, target interactions, and clinical outcomes
  • 6.2.6 SAFETY & TOXICITY
    • 6.2.6.1 Building generalizable model for toxicity and off-target effect prediction
  • 6.2.7 CLINICAL DEVELOPMENT
    • 6.2.7.1 Designing and conducting clinical trials for personalized dosing, targeted therapies
• 6.3 DIAGNOSTICS & SCREENING
  • 6.3.1 RISK ASSESSMENT & PATIENT STRATIFICATION
    • 6.3.1.1 Leveraging AI to personalize treatment plan
  • 6.3.2 DISEASE SCREENING
    • 6.3.2.1 Leveraging machine learning to peruse and resolve complex patient data
  • 6.3.3 DISEASE DIAGNOSIS
    • 6.3.3.1 Identifying biomarkers for precise treatment
  • 6.3.4 DISEASE PROGRESSION, STAGING, AND PROGNOSIS
    • 6.3.4.1 Using AI to track disease conditions
• 6.4 THERAPEUTICS
  • 6.4.1 THERAPY SELECTION & PLANNING
    • 6.4.1.1 Leveraging generative models to predict and design suitable treatment
  • 6.4.2 THERAPY MONITORING
    • 6.4.2.1 Need to effectively track safety and efficacy of treatment
  • 6.4.3 POST-TREATMENT SURVEILLANCE & FOLLOW-UP
    • 6.4.3.1 AI algorithms to identify subtle patterns in data, allowing for early detection of potential issues

7 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA

• 7.1 INTRODUCTION
• 7.2 ONCOLOGY
  • 7.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS
• 7.3 RARE DISEASES
  • 7.3.1 COMBATING CHALLENGING THERAPEUTICS DUE TO COMPLEX AND HETEROGENEOUS NATURE OF RARE DISEASES
• 7.4 INFECTIOUS DISEASES
  • 7.4.1 NEED FOR INNOVATION IN INFECTIOUS DISEASE TREATMENT, ESPECIALLY AFTER IMPACT OF COVID-19
• 7.5 NEUROLOGY
  • 7.5.1 SHORTAGE AND COMPLEXITY OF NEURODEGENERATIVE DISEASES
• 7.6 CARDIOLOGY
  • 7.6.1 WIDE RANGE AND INCIDENCE OF CARDIOVASCULAR DISEASES
• 7.7 HEMATOLOGY
  • 7.7.1 AI-DRIVEN ALGORITHMS TO ANALYZE BLOOD SAMPLES, IMAGING DATA, AND GENOMIC PROFILES TO DETECT ABNORMALITIES
• 7.8 OTHER THERAPEUTIC AREAS

8 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT

• 8.1 INTRODUCTION
• 8.2 SOFTWARE
  • 8.2.1 SCALABILITY AND FLEXIBILITY OF AI SOFTWARE TO ENHANCE EFFICIENCY OF CLINICAL WORKFLOWS
• 8.3 SERVICES
  • 8.3.1 NEED FOR EXPERT ASSISTANCE AMONG HEALTHCARE ORGANIZATIONS IN ADOPTING AND OPTIMIZING AI TECHNOLOGIES

9 AI IN PRECISION MEDICINE MARKET, BY TOOL

• 9.1 INTRODUCTION
• 9.2 MACHINE LEARNING
  • 9.2.1 DEEP LEARNING
    • 9.2.1.1 Convolutional neural networks
      • 9.2.1.1.1 Interpreting complex biological data to enable personalizing healthcare
    • 9.2.1.2 Recurrent neural networks (RNNs)
      • 9.2.1.2.1 Optimizing clinical data to model patient trajectories by analyzing longitudinal data
    • 9.2.1.3 Generative adversarial networks (GANs)
      • 9.2.1.3.1 GAN to focus on new molecules and biological datasets
    • 9.2.1.4 Graph neural networks (GNNs)
      • 9.2.1.4.1 Predicting drug-drug interactions to optimize personalized treatment
    • 9.2.1.5 Other deep learning tools
  • 9.2.2 SUPERVISED MACHINE LEARNING
  • 9.2.3 REINFORCEMENT MACHINE LEARNING
  • 9.2.4 UNSUPERVISED MACHINE LEARNING
  • 9.2.5 OTHER MACHINE LEARNING TOOLS
• 9.3 NATURAL LANGUAGE PROCESSING
  • 9.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO BE INTERPRETED
• 9.4 CONTEXT-AWARE PROCESSING & COMPUTING
  • 9.4.1 TAILORING PATIENT CARE IN REAL TIME TO ENHANCE PRECISION MEDICINE
• 9.5 COMPUTER VISION
  • 9.5.1 INCREASE IN USE OF IMAGING BIOMARKERS TO SUPPORT SURGICAL PRECISION
• 9.6 IMAGE ANALYSIS
  • 9.6.1 HARNESSING MACHINE LEARNING TO AUTOMATE TECHNIQUES SUCH AS QUANTITATIVE IMAGING AND RADIOMICS
• 9.7 OTHER TOOLS

10 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT

• 10.1 INTRODUCTION
• 10.2 CLOUD-BASED MODEL
  • 10.2.1 RESEARCH COLLABORATION AND COST-EFFICIENCY OF CLOUD DEPLOYMENT
• 10.3 ON-PREMISE MODEL
  • 10.3.1 EASIER TO SECURE PATIENT DATA AND ENSURE COMPLIANCE IN ON-PREMISE AI-DRIVEN PRECISION MEDICINE
• 10.4 HYBRID MODEL
  • 10.4.1 HYBRID MODELS TO ENHANCE FLEXIBILITY AND SECURITY

11 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HEALTHCARE PROVIDERS
  • 11.2.1 REVOLUTIONIZING PATIENT CARE AND TREATMENT DELIVERY THROUGH ADVANCED TECHNOLOGIES
• 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.3.1 DRIVING DRUG DEVELOPMENT EFFICIENCY TO DESIGN ADAPTIVE TRIAL PROTOCOLS AND OPTIMIZE TREATMENT
• 11.4 MEDICAL DEVICE & EQUIPMENT COMPANIES
  • 11.4.1 INTEGRATION OF AI IN MEDICAL DEVICES TO ENHANCE PRECISION AND PERSONALIZED HEALTHCARE
• 11.5 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
  • 11.5.1 AI IN ACADEMIC INSTITUTES AND PUBLIC SECTOR COLLABORATIONS TO ACCELERATE INNOVATION AND RESEARCH
• 11.6 OTHER END USERS

12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American market with advanced regulatory system
  • 12.2.3 CANADA
    • 12.2.3.1 Emergence of new AI-based startups and high health expenditure
• 12.3 EUROPE
  • 12.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 12.3.2 UK
    • 12.3.2.1 Favorable government R&D investment and collaborations focused on drug discovery
  • 12.3.3 GERMANY
    • 12.3.3.1 Growing R&D investment by pharma and biotech companies
  • 12.3.4 FRANCE
    • 12.3.4.1 Strong government support through investments in initiatives
  • 12.3.5 ITALY
    • 12.3.5.1 Government Initiatives addressing local healthcare challenges through studies aimed at broader precision medicine strategies
  • 12.3.6 SPAIN
    • 12.3.6.1 High investments by pharmaceutical companies
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 12.4.2 JAPAN
    • 12.4.2.1 High investment in R&D and government initiatives focused on treatment outcomes
  • 12.4.3 CHINA
    • 12.4.3.1 Government funding to advance data analysis and international collaborations to develop targeted therapies
  • 12.4.4 INDIA
    • 12.4.4.1 High growth of pharmaceutical and medical device industries
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.5.2 BRAZIL
    • 12.5.2.1 Increase in governmental support through initiatives such as Brazilian Artificial Intelligence Plan
  • 12.5.3 MEXICO
    • 12.5.3.1 High potential to become leader in terms of readiness in technology
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 13.3 REVENUE ANALYSIS, 2019-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.4.1 RANKING OF KEY MARKET PLAYERS
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Therapeutic area footprint
    • 13.5.5.3 End user footprint
    • 13.5.5.4 Component footprint
    • 13.5.5.5 Deployment footprint
    • 13.5.5.6 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 13.6.5.1 Detailed list of key startup/SME players
    • 13.6.5.2 Competitive benchmarking of key emerging players/startups, by region
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 COMPANY VALUATION
  • 13.7.2 FINANCIAL METRICS
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
  • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 NVIDIA CORPORATION
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services/Solutions offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches
      • 14.1.1.3.2 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 EXSCIENTIA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services/Solutions offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
      • 14.1.2.3.4 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 GOOGLE
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services/Solutions offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 ILLUMINA, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services/Solutions offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 TEMPUS AI, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services/Solutions offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
      • 14.1.5.3.3 Expansions
      • 14.1.5.3.4 Other developments
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 BENEVOLENTAI
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services/Solutions offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 MICROSOFT CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services/Solutions offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 IBM
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services/Solutions offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 GE HEALTHCARE
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services/Solutions offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches
      • 14.1.9.3.2 Deals
      • 14.1.9.3.3 Other developments
  • 14.1.10 DEEP GENOMICS
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services/Solutions offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Other developments
  • 14.1.11 SIEMENS HEALTHINEERS AG
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Solutions/Services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 BIOXCEL THERAPEUTICS, INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Solutions/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
      • 14.1.12.3.2 Other developments
  • 14.1.13 INSILICO MEDICINE
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services/Solutions offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Other developments
  • 14.1.14 PATHAI, INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services/Solutions offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches
      • 14.1.14.3.2 Deals
      • 14.1.14.3.3 Other developments
  • 14.1.15 VERGE GENOMICS
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services/Solutions offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Deals
  • 14.1.16 GUARDANT HEALTH, INC.
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products/Services/Solutions offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Product launches
      • 14.1.16.3.2 Deals
      • 14.1.16.3.3 Other developments
  • 14.1.17 GRAIL, INC.
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products/Services/Solutions offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Deals
  • 14.1.18 FOUNDATION MEDICINE, INC.
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products/Services/Solutions offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Deals
      • 14.1.18.3.2 Other developments
  • 14.1.19 PROSCIA INC.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products/Services/Solutions offered
    • 14.1.19.3 Recent developments
      • 14.1.19.3.1 Product launches
      • 14.1.19.3.2 Deals
      • 14.1.19.3.3 Other developments
  • 14.1.20 FLATIRON HEALTH
    • 14.1.20.1 Business overview
    • 14.1.20.2 Products/Services/Solutions offered
    • 14.1.20.3 Recent developments
      • 14.1.20.3.1 Deals
      • 14.1.20.3.2 Other developments
• 14.2 OTHER PLAYERS
  • 14.2.1 PREDICTIVE ONCOLOGY
  • 14.2.2 PAIGE AI, INC.
  • 14.2.3 DENSITAS INC.
  • 14.2.4 ZEPHYR AI, INC.
  • 14.2.5 NUCLEAI, INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 AI IN PRECISION MEDICINE MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET DYNAMICS: IMPACT ANALYSIS
• TABLE 3 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021-2024
• TABLE 4 BIGGEST HEALTHCARE SECURITY BREACHES, 2023
• TABLE 5 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
• TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 NORTH AMERICA: REGULATORY SCENARIO
• TABLE 13 EUROPE: REGULATORY SCENARIO
• TABLE 14 ASIA PACIFIC: REGULATORY SCENARIO
• TABLE 15 MIDDLE EAST & AFRICA: REGULATORY SCENARIO
• TABLE 16 LATIN AMERICA: REGULATORY SCENARIO
• TABLE 17 INDICATIVE PRICING FOR KEY PLAYERS, 2023 (USD)
• TABLE 18 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION, 2022-2024 (USD)
• TABLE 19 AI IN PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE
• TABLE 21 AI IN PRECISION MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
• TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS
• TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
• TABLE 24 UNMET NEEDS IN AI IN PRECISION MEDICINE MARKET
• TABLE 25 END-USER EXPECTATIONS IN AI IN PRECISION MEDICINE MARKET
• TABLE 26 KEY CONFERENCES & EVENTS, 2024-2025
• TABLE 27 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 28 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 29 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 30 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR UNDERSTANDING DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 31 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG REPURPOSING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 32 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DE NOVO DRUG DESIGN, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 33 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG OPTIMIZATION, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 34 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SAFETY & TOXICITY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 35 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLINICAL DEVELOPMENT, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 36 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DIAGNOSTICS & SCREENING, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 37 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 38 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE SCREENING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 39 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 40 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE PROGRESSION, STAGING, AND PROGNOSIS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 41 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPEUTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 42 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY SELECTION & PLANNING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 43 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY MONITORING, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR POST-TREATMENT SURVEILLANCE & FOLLOW-UP, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 47 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 48 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 49 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 50 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOLOGY
• TABLE 51 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CARDIOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 52 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 53 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 54 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 55 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SOFTWARE, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 56 ARTIFICIAL INTELLIGENCE SERVICES IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 57 AI IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 58 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 59 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 60 DEEP LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 61 CONVOLUTIONAL NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 62 RECURRENT NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 63 GENERATIVE ADVERSARIAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 64 GRAPH NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 65 OTHER DEEP LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 66 SUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 67 REINFORCEMENT LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 68 UNSUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 69 OTHER MACHINE LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 70 NATURAL LANGUAGE PROCESSING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 71 CONTEXT-AWARE PROCESSING & COMPUTING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 72 COMPUTER VISION AI IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 73 IMAGE ANALYSIS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 74 OTHER AI TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 75 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 76 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLOUD-BASED MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 77 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR ON-PREMISE MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 78 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HYBRID MODEL, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 79 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 80 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 81 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 82 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR MEDICAL DEVICE & EQUIPMENT COMPANIES, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 83 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 84 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2022-2030 (USD MILLION)
• TABLE 85 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 91 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
• TABLE 92 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 93 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 94 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 95 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 96 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 97 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
• TABLE 98 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 102 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 103 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022-2030 (USD MILLION)
• TABLE 104 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 109 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 110 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 111 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 114 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 115 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 116 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 117 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 121 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 122 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 123 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 127 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 128 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 129 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 130 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 131 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 132 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 133 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 134 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 135 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 136 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 137 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 138 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 139 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 140 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 141 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 142 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 143 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 144 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 145 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 146 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 147 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 148 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 149 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 150 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 151 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 152 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 153 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 154 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 155 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 156 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 157 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 158 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 159 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 160 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 161 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 162 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 163 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 164 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 165 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 166 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 167 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 168 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 169 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 170 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 171 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 172 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 173 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 174 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 175 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 176 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 177 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 178 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 179 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 180 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 181 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 182 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 183 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 184 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 185 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 186 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 187 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 188 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 189 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 190 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 191 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 192 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 193 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 194 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 195 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 196 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 197 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 198 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 199 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 200 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 201 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 202 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 203 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 204 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 205 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 206 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 207 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 208 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 209 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 210 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 211 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 212 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 213 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 214 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 215 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 216 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 217 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 218 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
• TABLE 219 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022-2030 (USD MILLION)
• TABLE 220 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022-2030 (USD MILLION)
• TABLE 221 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022-2030 (USD MILLION)
• TABLE 222 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI PRECISION MEDICINE MARKET, JANUARY 2021-OCTOBER 2024
• TABLE 224 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEGREE OF COMPETITION
• TABLE 225 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT, 2023
• TABLE 226 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: END USER FOOTPRINT, 2023
• TABLE 227 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPONENT FOOTPRINT, 2023
• TABLE 228 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEPLOYMENT FOOTPRINT, 2023
• TABLE 229 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: REGION FOOTPRINT, 2023
• TABLE 230 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS, 2023
• TABLE 231 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION, 2023
• TABLE 232 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 233 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEALS, J ANUARY 2021-OCTOBER 2024
• TABLE 234 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 235 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 236 NVIDIA CORPORATION: COMPANY OVERVIEW
• TABLE 237 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 238 NVIDIA CORPORATION: PRODUCT LAUNCHES
• TABLE 239 NVIDIA CORPORATION: DEALS
• TABLE 240 EXSCIENTIA: COMPANY OVERVIEW
• TABLE 241 EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 242 EXSCIENTIA: PRODUCT LAUNCHES
• TABLE 243 EXSCIENTIA: DEALS
• TABLE 244 EXSCIENTIA: EXPANSIONS
• TABLE 245 EXSCIENTIA: OTHER DEVELOPMENTS
• TABLE 246 GOOGLE: COMPANY OVERVIEW
• TABLE 247 GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 248 GOOGLE: PRODUCT LAUNCHES
• TABLE 249 GOOGLE: DEALS
• TABLE 250 GOOGLE: EXPANSIONS
• TABLE 251 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 252 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 253 ILLUMINA, INC.: PRODUCT LAUNCHES
• TABLE 254 ILLUMINA, INC.: DEALS
• TABLE 255 TEMPUS: COMPANY OVERVIEW
• TABLE 256 TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 257 TEMPUS: PRODUCT LAUNCHES
• TABLE 258 TEMPUS: DEALS
• TABLE 259 TEMPUS: EXPANSIONS
• TABLE 260 TEMPUS: OTHER DEVELOPMENTS
• TABLE 261 BENEVOLENTAI: COMPANY OVERVIEW
• TABLE 262 BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 263 BENEVOLENTAI: DEALS
• TABLE 264 MICROSOFT CORPORATION: COMPANY OVERVIEW
• TABLE 265 MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 266 MICROSOFT CORPORATION: DEALS
• TABLE 267 IBM: COMPANY OVERVIEW
• TABLE 268 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 269 IBM: DEALS
• TABLE 270 GE HEALTHCARE: COMPANY OVERVIEW
• TABLE 271 GE HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 272 GE HEALTHCARE: PRODUCT LAUNCHES
• TABLE 273 GE HEALTHCARE: DEALS
• TABLE 274 GE HEALTHCARE: OTHER DEVELOPMENTS
• TABLE 275 DEEP GENOMICS: COMPANY OVERVIEW
• TABLE 276 DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 277 DEEP GENOMICS: PRODUCT LAUNCHES
• TABLE 278 DEEP GENOMICS: DEALS
• TABLE 279 DEEP GENOMICS: OTHER DEVELOPMENTS
• TABLE 280 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 281 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED
• TABLE 282 SIEMENS HEALTHINEERS AG: DEALS
• TABLE 283 BIOXCEL THERAPEUTICS, INC.: COMPANY OVERVIEW
• TABLE 284 BIOXCEL THERAPEUTICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
• TABLE 285 BIOXCEL THERAPEUTICS, INC.: DEALS
• TABLE 286 BIOXCEL THERAPEUTICS, INC.: OTHER DEVELOPMENTS
• TABLE 287 INSILICO MEDICINE: COMPANY OVERVIEW
• TABLE 288 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 289 INSILICO MEDICINE: PRODUCT LAUNCHES
• TABLE 290 INSILICO MEDICINE: DEALS
• TABLE 291 INSILICO MEDICINE: OTHER DEVELOPMENTS
• TABLE 292 PATHAI, INC.: COMPANY OVERVIEW
• TABLE 293 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 294 PATHAI, INC.: PRODUCT LAUNCHES
• TABLE 295 PATHAI, INC.: DEALS
• TABLE 296 PATHAI, INC.: OTHER DEVELOPMENTS
• TABLE 297 VERGE GENOMICS: COMPANY OVERVIEW
• TABLE 298 VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 299 VERGE GENOMICS: DEALS
• TABLE 300 GUARDANT HEALTH, INC.: COMPANY OVERVIEW
• TABLE 301 GUARDANT HEALTH, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 302 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES
• TABLE 303 GUARDANT HEALTH, INC.: DEALS
• TABLE 304 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS
• TABLE 305 GRAIL, INC.: COMPANY OVERVIEW
• TABLE 306 GRAIL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 307 GRAIL, INC.: DEALS
• TABLE 308 FOUNDATION MEDICINE, INC.: COMPANY OVERVIEW
• TABLE 309 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 310 FOUNDATION MEDICINE, INC.: DEALS
• TABLE 311 FOUNDATION MEDICINE, INC.: OTHER DEVELOPMENTS
• TABLE 312 PROSCIA INC.: COMPANY OVERVIEW
• TABLE 313 PROSCIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 314 PROSCIA INC.: PRODUCT LAUNCHES
• TABLE 315 PROSCIA INC.: DEALS
• TABLE 316 PROSCIA INC.: OTHER DEVELOPMENTS
• TABLE 317 FLATIRON HEALTH: COMPANY OVERVIEW
• TABLE 318 FLATIRON HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 319 FLATIRON HEALTH: DEALS
• TABLE 320 FLATIRON HEALTH: OTHER DEVELOPMENTS
• TABLE 321 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
• TABLE 322 PAIGE AI, INC.: COMPANY OVERVIEW
• TABLE 323 DENSITAS INC.: COMPANY OVERVIEW
• TABLE 324 ZEPHYR AI, INC.: COMPANY OVERVIEW
• TABLE 325 NUCLEAI, INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 AI IN PRECISION MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 STUDY YEARS CONSIDERED
• FIGURE 3 RESEARCH DESIGN
• FIGURE 4 PRIMARY SOURCES
• FIGURE 5 INSIGHTS FROM PRIMARY EXPERTS
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 8 TOP-DOWN APPROACH
• FIGURE 9 CAGR PROJECTIONS, BY MARKET DYNAMIC, 2024-2030
• FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 11 DATA TRIANGULATION
• FIGURE 12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
• FIGURE 13 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2024 VS. 2030 (USD MILLION)
• FIGURE 14 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2024 VS. 2030 (USD MILLION)
• FIGURE 15 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2024 VS. 2030 (USD MILLION)
• FIGURE 16 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2024 VS. 2030 (USD MILLION)
• FIGURE 17 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
• FIGURE 18 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHICAL SNAPSHOT
• FIGURE 19 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
• FIGURE 20 NORTH AMERICA TO DOMINATE AI IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD
• FIGURE 21 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
• FIGURE 24 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 25 APPROVAL RATE OF PERSONALIZED MEDICINES BY US FDA, 2015-2023
• FIGURE 26 HEALTH SECURITY BREACHES, 2009-2023
• FIGURE 27 INDIVIDUALS AFFECTED BY HEALTHCARE SECURITY BREACHES, 2009-2023 (MILLION)
• FIGURE 28 USE CASES FOR PREDICTIVE ANALYTICS IN HEALTHCARE
• FIGURE 29 REVENUE SHIFT IN AI IN PRECISION MEDICINE MARKET
• FIGURE 30 AI IN PRECISION MEDICINE MARKET: ECOSYSTEM ANALYSIS
• FIGURE 31 AI IN PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS, 2023
• FIGURE 32 AI IN PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 33 JURISDICTION ANALYSIS: TOP PATENT APPLICANT COUNTRIES, JANUARY 2015-NOVEMBER 2024
• FIGURE 34 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET, JANUARY 2015- NOVEMBER 2024
• FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
• FIGURE 36 KEY BUYING CRITERIA FOR END USERS
• FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING AI IN PRECISION MEDICINE ACROSS INDUSTRIES
• FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
• FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT
• FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT
• FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2019-2023 (USD MILLION)
• FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: RANKING OF KEY PLAYERS, 2023
• FIGURE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 46 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY FOOTPRINT, 2023
• FIGURE 47 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
• FIGURE 49 EV/EBITDA OF KEY VENDORS, 2024
• FIGURE 50 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 51 NVIDIA CORPORATION: COMPANY SNAPSHOT
• FIGURE 52 EXSCIENTIA: COMPANY SNAPSHOT
• FIGURE 53 GOOGLE: COMPANY SNAPSHOT
• FIGURE 54 ILLUMINA, INC.: COMPANY SNAPSHOT
• FIGURE 55 BENEVOLENTAI: COMPANY SNAPSHOT
• FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT
• FIGURE 57 IBM: COMPANY SNAPSHOT
• FIGURE 58 GE HEALTHCARE: COMPANY SNAPSHOT
• FIGURE 59 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
• FIGURE 60 GUARDANT HEALTH: COMPANY SNAPSHOT